Merck KGaA Previews Cladribine Regulatory Revival Story At ECTRIMS
Executive Summary
With the EMA’s review of the latest MAA for cladribine ongoing, Merck KGaA uses ECTRIMS 2016 to showcase longer-term efficacy data and a safety analysis that could lay to rest concerns about the multiple sclerosis therapy's risk of malignancy.
You may also be interested in...
Merck KGaA's MS Drug Mavenclad May Defy Doubters
The German group's oral treatment is late coming to the market but a key opinion leader believes that it will change the way multiple sclerosis is treated.
Multiple Sclerosis: Close To Being Conquered
The development of a plethora of new medicines for multiple sclerosis over the past 10 years is truly remarkable. As well as the dozen or so agents now available to treat relapsing MS, the first potential product for the poorly treated condition, primary progressive MS, is nearing the market.
ECTRIMS 2016: What Future For Merck KGaA’s Cladribine?
With the EMA’s review of the latest MAA for cladribine ongoing, Merck KGaA is using ECTRIMS 2016 as the stage for numerous new presentations on the drug’s efficacy and safety. Data on this additional induction therapy are positive but regulators and the market could prove difficult to persuade.